Search

everythinglearnresearchcommunity

for

Search:↓

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Surgery removed ovarian tumors, normalizing testosterone and improving symptoms.

A postmenopausal woman with hair loss and hirsutism improved after surgery to remove an ovarian tumor.

Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.

A postmenopausal woman's hair loss and excess hair growth improved after surgery for ovarian hyperthecosis.

A thorough diagnostic process and teamwork are crucial for managing complex hyperandrogenism in postmenopausal women.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Biochemical markers help diagnose ovarian tumors in postmenopausal women.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

A postmenopausal woman's increased male hormone levels were successfully treated with surgery.

Aromatase inhibitors cause male pattern hair loss in women.

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

An ovarian tumor caused a woman's male-like symptoms, which improved after surgery.

Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.

Women with PCOS may have a reduced ability to fight breast tumor cells over time.

Benign conditions can mimic serious ones in postmenopausal hyperandrogenism, requiring careful diagnosis.

High androgen levels in postmenopausal women may suggest an ovarian tumor, and removing it can improve heart and metabolic health.

A postmenopausal woman's virilization was caused by a rare ovarian tumor that was hard to detect but was successfully treated with surgery.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

A postmenopausal woman had high testosterone from her right adrenal gland, leading to recommended surgery.

Hair loss during breast cancer treatment affects each woman differently, influenced by her environment and family.

Chemotherapy causes temporary hair loss in women, while Tamoxifen does not significantly affect hair, and genetics show no link between female pattern hair loss and common baldness genes.

Presurgical models can effectively and affordably screen cancer prevention agents.

Leydig cell tumors can cause hormone issues in postmenopausal women even if imaging looks normal.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

Ki-67 levels do not predict treatment response in triple-negative breast cancer.

Progesterone byproduct 5αP stimulates mammary tumor growth, but finasteride can suppress it.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.